TIAA FSB’s Lexicon Pharmaceuticals LXRX Stock Holding History

TIAA FSB’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$61.8K	Buy	+27,000	New	+$71.7K	﹤0.01%	567

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TIAA FSB's LXRX Position: Q2 2023 in Review

TIAA FSB opened a new position in Lexicon Pharmaceuticals (LXRX) in Q2 2023: 27,000 shares worth $61.8K. The stake represents ﹤0.01% of the portfolio and ranks #567 among its holdings.

123 funds tracked by Wall St. Rank hold LXRX as of Q2 2023.

TIAA FSB held 27,000 shares of Lexicon Pharmaceuticals worth $61.8K as of Q2 2023.
Lexicon Pharmaceuticals was a new TIAA FSB position in Q2 2023.
Lexicon Pharmaceuticals made up ﹤0.01% of TIAA FSB's portfolio in Q2 2023, its #567 holding.
123 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2023.

Based on TIAA FSB's 13F filing for Q2 2023, filed 31 Jul 2023.